Silencing of the MLH1 gene by promoter hypermethylation is the mechanism underlying the microsatellite instability (MSI) phenotype in endometrial cancers. However, the profile of CpG methylation in a wide range of MLH1 promoters in endometrial cancers and in the normal endometrium is largely unknown. The present study investigates the region 700 bp upstream of MLH1 covering 48 CpG sites using bisulfite sequencing. Methylation status was classified as full (over 80% of CpGs are methylated), partial (10-80%) or nonmethylation (less than 10%). Of 56 endometrioid endometrial cancers, 16 (29%) were fully methylated, 14 (25%) were partially methylated and 26 (46%) were not methylated. Analyses of MLH1 by immunohistochemical means and of MSI revealed that the degree, rather than region-specific methylation of CpG islands is critical for decreased MLH1 expression and the MSI phenotype. Among 12 patients with methylated cancers, five (42%) patients contained methylated promoters in their normal endometria with profiles similar to those of cancer lesions, and these were associated with the MSI phenotype. In contrast, only one of 31 (3%) normal endometria from patients without endometrial malignancies harbored methylated promoters. These findings suggest that hypermethylation of the MLH1 promoter is frequent in the histologically normal endometrium adjacent to cancers, supporting the notion that hypermethylation of mismatch repair genes is the initial step that triggers various genetic events in endometrial carcinogenesis.
Introduction
Endometrial carcinogenesis is a multistep process involving the abnormal function of cellular genes, including K-ras, p53 or PTEN, which are usually induced by genetic mutations (Inoue, 2001) . Another factor involving endometrial carcinogenesis is the genetic instability of microsatellite sequences, namely microsatellite instability (MSI), which are common in tumors associated with hereditary nonpolyposis colorectal cancer syndrome (HNPCC) (Ionov et al., 1993; Thibodeau et al., 1993; Burks et al., 1994; Duggan et al., 1994; Gurin et al., 1999) . The microsatellite instability phenotype is associated with the dysfunction of DNA mismatch repair genes (MMR), including MLH1 and MSH2, and HNPCC is generally associated with germline mutations in either of MLH1 and MSH2, with mutations of other mismatch repair genes being rare (Fishel et al., 1993; Bronner et al., 1994; Papadopoulos and Lindblom, 1997; Peltomaki and de la Chapelle, 1997) . However, in a significant subset of MSI-positive sporadic tumors including endometrial cancers, no mutations of mismatch repair genes were identified, indicating that nonmutational mechanisms are responsible for the defect (Katabuchi et al., 1995; Liu et al., 1995) .
Alternative modes of gene inactivation during the development of cancer include an epigenetic process marked by promoter region hypermethylation associated with transcriptional loss, as demonstrated for several tumor suppressor genes (Esteller et al., 2001) . The MLH1 promoter is frequently hypermethylated in colorectal and gastric tumors as well as in endometrial cancers associated with the MSI phenotype (Esteller et al., 1998; Herman et al., 1998; Toyota et al., 1999a, b; Simpkins et al., 1999) . Most of these studies examined the methylation status of the CpG sites within the limited areas of the MLH1 promoter, so the regions of methylated CpGs critical for gene silencing are not well understood. The present study investigates the methylation profile of a large number of CpG sites spread over the MLH1 promoter in endometrial cancers and examines whether specific methylated sites or regions of hypermethylated CpGs are critical to regulate protein expression or the MSI phenotype.
Emerging evidence shows that the MLH1 promoters in precursors of some tumor types are frequently hypermethylated, suggesting that these changes represent precursor lesions preceding the development of cancers (Esteller et al., 1999; Nakagawa et al., 2001) . However, little information is available about the methylation status of the MLH1 promoter in the normal endometrium. This study also examines the methylation status of the MLH1 promoter in normal areas of endometrium adjacent to endometrial cancers and compares the profiles with those in cancers.
Results

Methylation status of MLH1 promoter in endometrial cancers
We initially examined a consecutive series of 56 endometrioid endometrial cancers for MLH1 hypermethylation using methylation-specific PCR (MSP). Among 56 endometrial cancers, 21 (38%) were methylated in the MLH1 promoter whereas 35 (63%) were not ( Figure 1 ). We then analysed the methylation profile of CpG islands in the MLH1 promoter spanning À695 and À74 (first ATG of exon 1 is represented as +1) containing 48 CpGs using bisulfite sequencing (Figure 2 ). The findings were classified as fully methylated (over 80% methylated CpGs), partially methylated (10-80% methylated CpGs) and unmethylated (less than 10% methylated CpGs). In all, 16 samples (29%) were fully methylated, 14 (25%) were partially methylated and 26 (46%) were not methylated. Thus, bisulfite sequencing showed that alleles were methylated in 30 of 56 endometrial cancers (54%). The findings of MSP and bisulfite sequencing closely correlated ( Table 2) . The CpGs at the 5 0 -region appeared to be more preferentially methylated than those at the 3 0 -region of the promoter (Figure 2 ). The 5 0 -region between À694 and À670 corresponding to CpGs 42-48 in Figure 2 was methylated in more than 90% of the methylated samples. However, a computer-assisted search did not detect any known transcription factor binding sites in this region. A comparison of the status of MLH1 hypermethylation with clinicopathological features of the patients such as age, tumor stage and degree of differentiation (Table 1) , revealed no statistical correlation.
Degree rather than region-specificity of MLH1 methylation is critical for loss of protein expression and the MSI phenotype To examine the relation between the status of promoter methylation and protein expression of MLH1, we immunohistochemically analysed MLH1 in 32 patients, whose samples were surgically obtained within 3 years. Expression of MLH1 was observed in normal endometrial glands as well as in the stromal tissues of all samples examined (Figure 3c ). In contrast, MLH1 expression was decreased or absent in some cancer samples. When staining was classified as intense (over 75% positive in tumor cells), intermediate (25-75% positive in tumor cells), or weak/absent (less than 25% positive in tumor cells), 8, 15 and 9, respectively, were stained in endometrial cancers (Figure 3a-c) . We then examined the correlation between protein expression and promoter hypermethylation. The MLH1 promoter was fully methylated in eight of the nine samples with weak or absent expression, whereas none of the eight samples with intense expression were methylated. Two of the 15 samples with intermediate expression were fully methylated, whereas five and two were partially methylated and not methylated, respectively. The correlation between expression and promoter hypermethylation of MLH1 was significant (Po0.001: Fisher's exact method). In cancer samples with weak or little MLH1 expression, some normal endometrial glands adjacent to cancer lesions had lost MLH1 expression (Figure 3c ).
Microsatellite instability (MSI) was next investigated in the seven fully methylated, three partially methylated and seven unmethylated samples of endometrial cancers (Figure 4 , Table 3 ). Myometrial tissue samples collected at surgery served as controls for MSI analyses. Six of the seven fully methylated samples were MSI-positive while six of the seven nonmethylated samples were MSInegative. All three partially methylated samples were MSI-negative. Thus, MSI phenotype and MLH1 hypermethylation significantly correlated (P ¼ 0.011: Fisher's exact method).
MLH1 promoter is frequently hypermethylated in normal endometrium of patients with endometrial cancers and is associated with MSI phenotype
We investigated the methylation status of the MLH1 promoter by MSP in normal endometrium adjacent to methylated endometrial cancers from 12 patients. Normal endometria from 31 patients with benign uterine diseases at sites other than the endometrium or ovarian tumors were also examined. Among 12 fully or partially methylated endometrial cancer samples, the (Table 4 ). These five samples were further analysed by bisulfite sequencing. Both cancerous and normal endometria from the four samples were fully methylated, and the methylation profiles of the normal endometria were similar to that in cancer lesions ( Figure 5 ). The promoters in the other normal and cancerous endometria were partially (38% of CpGs methylated) and fully methylated (85% of CpGs methylated). In this sample, the methylation status of the CpGs at the 5 0 -region was similar in normal and cancer lesions. Normal endometrial samples from 31 patients with benign uterine diseases or ovarian tumors were analysed by MSP. The promoters of all but one (97%) were unmethylated. One methylated sample was from a 70-year-old woman with carcinoma in situ of the uterine cervix that had undergone surgery (hysterectomy). Histologically, endometrial diseases were undetectable in this patient. Taken together, these findings indicate that normal endometria adjacent to endometrial cancers are fre- Finally, we examined whether methylation of the MLH1 promoter is associated with the MSI phenotype in the normal endometrium (Figure 4, Table 3b ). We investigated the presence of MSI in 17 normal endometria adjacent to endometrial cancers. Three of four normal endometria with methylated promoters were MSI-positive, while 11 of 12 unmethylated samples were MSI-negative. Thus, MLH1 hypermethylation and the MSI phenotype significantly correlated in normal endometria adjacent to endometrial cancers (Po0.01: Fisher's exact method).
Discussion
The present study showed that hypermethylation of the MLH1 promoter is frequent in endometrial cancers, consistent with previous observations (Esteller et al., 1998; Gurin et al., 1999; Simpkins et al., 1999) . Approximately 50% of endometrial cancers had methylated alleles, whereas only 3% of the normal endometria from control patients were methylated, supporting the notion that hypermethylation of the MLH1 promoter plays a role in endometrial carcinogenesis. Bisulfite sequencing revealed variations in the methylation profiles of CpGs. Among 56 endometrial cancer samples, 16 (29%) were fully methylated, while 14 (25%) were partially methylated and 26 (46%) were not methylated. Immunohistochemical analyses revealed that hypermethylation of MLH1 was significantly associated with decreased protein expression. Deng et al. (1999) have recently correlated a small proximal region between À272 and À202 (the first ATG is represented as +1) in the promoter with the absence of MLH1 expression in colorectal cancer cell lines. They also demonstrated that methylation at a CpG near the CCAAT motif in MLH1 promoter interferes with its binding to the transcription factor, CBF, leading to the inhibition of gene expression in colorectal cancers (Deng et al., 2001) . The CCAAT sequence and the adjacent CpG described by Deng et al. are located at À285 and Figure 5 Bisulfite sequencing of MLH1 promoter in endometrial cancers and corresponding normal endometria. Map of the 5 0 promoter region shows individual CpG sites represented by vertical lines. Each horizontal compartment represents one sample of endometrial cancer and corresponding normal endometria. A total 48 CpGs within 700-bp upstream of the MLH1 promoter are numbered 1-48 (top). Open arrowhead indicates transcriptional start site of MLH1, and closed arrowhead indicates first ATG of exon 1, represented as +1. Open and filled boxes represent unmethylated and methylated CpGs, respectively. Ca, endometrial cancer lesions; N, corresponding normal endometrium À289 (CpG no. 12 in Figure 2) , respectively. However, we did not find that methylation of this CpG was prevalent in endometrial cancers. Thus, our data using clinical samples did not agree with the observations of Deng et al. using colorectal cancer cell lines. The reasons for this discrepancy remain unclear, but the methylation profiles of MLH1 might be tumor type-specific. We found that a series of CpGs at the 5 0 -region between À694 and À670 were preferentially methylated in endometrial cancers. However, a computer-assisted sequence analysis did not reveal any known specific transcription factorbinding sites in this region. Our data thus support the notions that the degree, rather than the region specificity of methylation targeting specific transcription factor binding sites is responsible for transcriptional silencing and the decreased expression of MLH1 protein. We found a significant correlation between the methylation status of MLH1 and the MSI phenotype. This is consistent with the proposed concept that silencing of the MLH1 promoter by hypermethylation and the subsequent loss of protein expression causes defects in mismatch repair, leading to the MSI phenotype.
The present study found frequent hypermethylation of MLH1 in the normal endometrium of patients with endometrial cancers. In cancer patients with hypermethylated promoters, approximately 40% of the adjacent normal endometria also had methylated promoters. Endometrial cancers frequently involve hyperplasias in adjacent areas, which sometimes appear macroscopically normal. We therefore confirmed that adjacent normal regions that we collected did not include hyperplasia according to histological examinations by three independent pathologists. Notably, we found that some normal endometrial glands adjacent to MLH1-negative endometrial cancers also lacked MLH1 expression (Figure 3c ). Although, we did not analyse the methylation status of MLH1 in individual glands by microdissection techniques, these apparently normal glands might have methylated promoters, which might be latent precancers. The methylation profiles of adjacent normal endometria were concordant with those in cancer lesions in four of five concurrent methylated samples. The remaining one sample (Patient 16) exhibited 38 and 85% methylation of CpGs in normal endometrium and in cancer lesions, respectively ( Figure 5 ). The methylated status of the CpGs at the 5 0 -region was almost concordant in normal and cancer lesions. These findings further support the notion that the MLH1 promoter becomes hypermethylated during the early stages of endometrial carcinogenesis. We also investigated the prevalence of MLH1 hypermethylation in normal control patients. Alleles in all but one of 31 (3%) normal endometria in the patients with benign uterine diseases or ovarian tumors were methylated. Thus, hypermethylation of the MLH1 promoter is specific to the normal endometria concurrent with endometrial cancers. Recent studies have demonstrated that the MLH1 promoter is methylated in endometrial hyperplasia (Esteller et al., 1999) . Although we did not examine such samples, our data do not contradict this finding and extend the concept that the MLH1 promoter is already hypermethylated in the normal endometrium. We further examined the MSI status in these normal endometria and identified a close correlation between hypermethylation of MLH1 and the MSI phenotype, suggesting that hypermethylation of MLH1 significantly influences MSI phenotype in the normal endometrium and may be the initial step for endometrial carcinogenesis.
Somatic mutation or deletion of the PTEN tumor suppressor gene is frequently observed in endometrioid endometrial cancers (Tashiro et al., 1997; Mutter et al., 2000) and the loss of PTEN function by these abnormalities is known to play a pivotal role in endometrial carcinogenesis. It is of interest to identify whether MLH1 hypermethylation or MSI+ induce PTEN mutation. The recent study by Zhou et al. (2002) demonstrated that MSI+ does not necessarily precede PTEN somatic mutation in sporadic endometrial cancers. In addition, PTEN somatic mutation has been shown in endometrial precancers and even normal glands (Mutter et al., 2000 (Mutter et al., , 2001 . These studies may contradict our hypothesis that MLH1 hypermethylation may be the initial events that trigger the genetic alterations involved in endometrial carcinogenesis. Since we did not examine the status of PTEN mutation in endometrial cancers, it remains unclear whether MLH1 hypermethylation is associated with PTEN mutation. To resolve this point, we are currently investigating the status of PTEN mutation in cases with or without MLH1 hypermethylation.
The assay system we used is based on the method of Nakagawa et al., in which nested PCR preferentially amplifies the methylated promoters using methylationspecific primers (Nakagawa et al., 2001) . Thus, a rare population with methylated alleles might have been detected. However, we showed that the results obtained using this and the standard MSP method closely correlated. Therefore, the nested-PCR-based assays probably did not exaggerate the frequency of methylation in the MLH1 promoter. Figure 3c shows that there are apparently normal glands adjacent to cancers, which lack MLH1 expression. High sensitivity of our method might help to detect aberrant methylation of MLH1 in these relatively rare glands.
In summary, we found that the MLH1 promoter is frequently methylated in the histologically normal endometrium of patients with endometrial cancers and that the methylation status is similar to that in cancer lesions. These findings support the notion that epigenetic changes in DNA mismatch repair genes might be the initial events that trigger the genetic alterations involved in endometrial carcinogenesis. In addition, irregular methylation of the MLH1 promoter could be a useful molecular marker with which to screen or diagnose precancerous and early endometrial malignancies.
Materials and methods
Tissue samples
All tumors and corresponding normal tissues were obtained from patients who underwent surgery to treat primary endometrial cancer at the Department of Obstetrics and Gynecology, Kanazawa University Hospital. All cancers were histologically confirmed as endometrioid adenocarcinoma of the uterus. Normal endometrial samples were also obtained from patients who underwent hysterectomy to treat other types of diseases such as uterine myoma, adenomyosis and ovarian tumors. All samples were collected after receiving written, informed consent from the patients. Half of the tissue samples were histologically examined, and the remaining portions of the samples were frozen at À801C until DNA extraction.
Methylation-specific PCR (MSP)
Genomic DNAs extracted from the samples using a QIAamp DNA Mini Kit (Qiagen, Valencia, CA, USA) were modified with sodium bisulfite using a CpGenome DNA Modification Kit (Intergen Co., Purchase, NY, USA), then methylationspecific PCR proceeded as described (Herman et al., 1996) . Briefly, genomic DNAs modified with sodium bisulfite served as templates for MSP using the primer sets specific for methylated and unmethylated versions of CpG islands in the MLH1 promoter. Primer sequences of MLH1 for the unmethylated reaction were 5 0 -TTTTGATGTAGATGTTT-TATTAGGGTTGT-3 0 (sense) and 5 . Universal methylated DNA (Intergen) also served as a positive control for the methylated status of MLH1. The PCR products were resolved by electrophoresis on a 3% agarose gel and visualized by ethidium bromide staining and UV illumination.
Bisulfite sequencing
Methylation status spanning the 5 0 -700-bp upstream region of MLH1 promoter was also examined by bisulfite sequencing as described (Nakagawa et al., 2001) . Briefly, methylated and unmethylated alleles from bisulfite-modified were DNA amplified using the primers MLH1-P1 (5 0 -TnTTAGGAGT-GAAGGAGGAGGTT-3 0 ) and MLH1-P3 (5 0 -ACCTTCAAC-CAATCACCTCAATA-3 0 ). Nested PCR followed using the methylation-specific primer MLH1-Pm (5 0 -ACGTA-GACGTTTTATTAGGGTCGC-3 0 ) and MLH1-P3. The PCR products were purified using a Qiagen Gel Extraction kit (Qiagen), cloned into the TA vector pGEM-T Easy (Promega, Madison, WI, USA), and sequenced. To examine methylation status among PCR clones, we compared the methylation profiles of five independent clones selected from five random endometrial cancer samples. We identified less than a 10% variation in the number of methylated CpGs among the clones under our assay conditions.
Immunohistochemistry
Immunohistochemical analyses of MLH1 were performed on formalin-fixed, paraffin-embedded specimens of endometrial tissues using the ABC-elite kit (Vector Laboratories Inc., Burlingame, CA, USA). The sections were autoclaved for 10 min in 1 Â Antigen Retrieval Solution (Biogenex, San Ramon, CA, USA), then incubated for 16 h at 41C with an MLH1 monoclonal antibody (PharMingen, San Diego, CA, USA; clone G168-15, code 13271A) at 10 mg/ml. Staining intensity was evaluated as ++(positive in over 75% of the tumor cells), +(25-75%), or À (less than 25%).
Analysis of MSI
Samples of DNA from endometrial cancers and normal areas of the endometrium were analysed using a panel of seven microsatellite markers for the dinucleotide repeat sequences, D2S119, D2S123, D2S147, D10S197, D13S175, D18S58 and D18S69 as described (Katabuchi et al., 1995) . Myometrial samples from each patient served as controls. The PCR products of the microsatellite markers were analysed using an ABI GeneScan (Applied Biosystems, Foster City, CA, USA). When the PCR bands had shifted compared with those of the myometrial control samples in two or more of the seven loci, the samples were classified as MSI-positive (Katabuchi et al., 1995) .
Statistical analysis
Statistical analysis was performed using Student's t-test and Fisher's exact method to evaluate the significance of the differences. A value of Po0.05 was considered statistically significant.
